Making Medicine

How can we create better outcomes for cancer patients? That's the big goal Mohit Manrao is aiming for in his work as SVP & Head of US Oncology at AstraZeneca. In this episode, Mohit shares his perspective on the future of oncology and the pursuit of patient-centric care in a post-Inflation Reduction Act world.Join us as we discuss:AstraZeneca's goal of launching 15 new drugs by 2030Solving for disparities in care and improving health equityTimeline for drug development and its effect on patient outcomes

Can we create a future healthcare system that is accessible and affordable for all patients?That's the major question that Mary R. Grealy, CEO of Healthcare Leadership Council, is trying to answer through her work. Mary, a former speech pathologist turned lawyer, shares insights from her unique journey from the healthcare field to advocating for patient-centered, value-based healthcare systems. In this wide-ranging conversation, Mary shares the challenges faced in the industry but also her hope for a future where patients are empowered through collaboration and innovation.Join us as we discuss:Why collaboration between stakeholders is keyPractical tips for advocates to make a compelling case to CongressThe potential effects of the new price-setting systemThe impact of proposed legislation on treatments and cures

With recent movement in healthcare including President Biden's Cancer Moonshot and the Inflation Reduction Act, one thing is clear: American healthcare is at a crossroads.As we begin to tackle the conversation of healthcare reform, how can we rebuild the system around patients?In this episode, MacKay Jimeson, Executive Director of The Patient Access & Affordability Project at Patients Rising, joins the show to explain how the system was never designed for patients, the benefits of a patient-centric system, and what the future holds for the industry.Join us as we discuss:Why patient-centricity is notably absent in our healthcare systemMacKay's op-ed in response to President Biden's SOTUThe impact of The Inflation Reduction Act and Centers for Medicare & Medicaid Services on today's healthcare landscapeThe true human impact of medicinesMacKay's Op-Ed: https://www.statnews.com/2023/02/09/state-of-the-union-highlights-americas-awkward-conversation-on-science-medicine-and-financing-the-development-of-new-medicines/MacKay's Bio:https://accessandaffordability.org/person/02-mackay-jimeson/

Even though 80% of the household decisions around health are made by women, only 4% of research and funding goes towards women's health research. In today's episode, Natalie Buford-Young, Chief Executive Officer at Springboard Enterprises, joins us to discuss Springboard's mission and how they are exploring a designated network to create pathways for emerging female innovators.We also get to hear about Natalie's experience testifying on the Hill to advocate for reducing the decline of women's entrepreneurship.Join us as we discuss:· Innovation in digital health and life sciences;· The Women's Health Innovation Coalition; and· Increasing diversity in clinical trials.

Runaway inflation and economic instability is terrible for just about everybody, but are efforts to tackle this problem creating more? To answer that, Kirsten Axelsen, Senior Policy Advisor at DLA Piper, joins the show to break down all the effects The Inflation Reduction act is having upon medicine, We discuss:The potential negative impacts on small-molecule medicineHow the act affects patents and generic medicineWhy we may see declines in small-molecule medicine research

John was at the JP Morgan conference and is here to discuss the key takeaways of the Inflation Reduction Act: the small-molecule penalty, the value of small-molecule drugs, the importance of incentivizing post-approval research, intellectual property, and non-coverage decisions at CMS. You'll also hear John's take on the demand for a more pro-patient agenda. There was a lot of focus on the role of policy and government, specifically in relation to the inflation reduction act and its impact on the life science and venture capital industries. Ready to reaffirm its values, Incubate will be focusing its energy on working with the White House and Congress to make necessary amendments to the legislation. They'll also have a focus on education and awareness to ensure that policymakers understand the critical role they play in the healthcare landscape.Join us as we discuss:Why is there excitement for 2023 in the biotech sector, but also some anxiety?How does the organization, Incubate, plan to address the inflation reduction act?What Congress can be doing to create a more pro-patient agenda?

How will the Inflation Reduction Act affect life sciences startups, current and future revenues, and drug investment? What will happen to patients amidst the aftermath of unintended consequences? There aren't too many people who know more about the ins and outs than the fine folks at DLA Piper.One of the biggest interventions in drug pricing since the Medicare Modernization Act was passed, listen to the inside scoop on what this means for the future of drugs.Join us as we discuss:-What drug price negotiations will look like under the act-How brand competition will play out-Which drugs and stakeholders will be affected

When you're working to make good investments in bio and med tech there are three key pillars to consider: science, the management team and finance. But how does it all come together in the end? Find out in the latest episode with Christine Brennan, Managing Director, Vertex Venture HC as we talk about Vertex's investment philosophy, why DEI inclusion is vital for industry, and what investments could look like for the rest of 2022.Join us as we discuss:Christine's journey to becoming the Managing Director at VertexThe investment firm's philosophy around Bio Tech, therapeutic investments and MedTechWhy it's so important for the next generation to have women in techAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

Everyone wants to make healthy choices. But we don't always have an opportunity to make healthy choices. In today's episode, we speak with Dr. Jerome Adams, Executive Director of Health Equity Initiatives at Purdue University and the 20th Surgeon General of the United States, about the need for proactive accessible health care, the economic burden of inaccessible healthcare, and why people need to know you care, before they care about what you knowAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

Investors are logical people. They invest in medicines that they expect will give them a return.Right now, there's far too little investment in developing new antibiotics. The pipeline of treatment is thin, but the need is greater than ever.Enter the AMR Action Fund.Hear our conversation with Dr. Henry Skinner, Chief Executive Officer at AMR Action Fund about:The increasing cost of AMR and policy challengesHow to build the pipeline to reach the new antibiotics we need to save millionsLeveraging healthcare innovation for AMR before it's too lateAMR Action Fund's first two investments and future outlook More information about Henry and today's topics:LinkedIn Profile: http://www.linkedin.com/in/henryskinner/Company Website: https://www.amractionfund.com/ As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

We'll be the first to say that the healthcare system is broken, especially in patient access complexity.However, we see three areas where we can execute actionable change for patients in 2022: intellectual property, mergers and acquisitions, and the FDA's reauthorization.In this episode, Coalition Manager and podcast host Ashlyn Roberts interviews John Stanford, Executive Director at Incubate Coalition, about opportunities for pro-patient reform.Join us as we discuss:A level set of what's been happening in Washington latelyWhy drug pricing issues are still evergreen3 areas for improvement: IP, M&A, and PDUFAShifting the narrative about pro-patient reformsAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

If we want data and clinical trials that meaningfully represent the population of people who take the drug, we'll need to do more than just issue guides.In this episode, we interview returning guest Kirsten Axelsen,Senior Advisor for Charles River Associates, about making medicine more accessible to lower income people and creating a more equitable health system with better data.Join us as we discuss:The detrimental effects of price controls on early life stages of drug developmentWhy a price control on one is a price control on allThe deep concerns about health disparity and equityHow data can address racism, ageism, and poverty in health systems2022 as the year of the non-COVID vaccineCheck out these resources we mentioned:Report referenced at 1:16 here and here.Build Back Better Act As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

Drug development is a relay race because you pass the baton to the next runner who will take it to the next level. You are proud to have made it onto the stairs at the end of the race not as an individual but as a huge team of experts of subsequent talents.In this episode we interview Johannes Fruehauf, Founder and CEO at LabCentral/BioLabs, about how the relay race metaphor shapes our understanding of drug development and why we need knowledgeable capital to forge ahead.Join us as we discuss:Solving challenges that face scaling entrepreneursThe stages of the drug development relay raceInvesting in a drug development ecosystem that diversifies talentThe need for investors who understand pharmaceutical startup proposals  As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

Drug policy debate today is like a wetland. It's the heart of the ecosystem that has to be preserved at all costs — or else we lose the wetlands, the shore, everything.In this episode, we interview Jean-Francois Formela, Partner at Atlas Venture, about what brought him to Washington and his views on the government's role in drug development.Join us as we discuss:Where are we going in drug developmentThe role of new modalitiesInvestor goals: great science, great company, good returnA future in which governments enable the biopharmaceutical community to cure diseaseTo hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

Today's guest describes drug development in the American healthcare market with the analogy of mortgages and rents.People would rather pay higher mortgages because they are finite than pay rent indefinitely. Market-based pricing means that drugs will cost more until they become generic, whereas price control means paying rent forever.In this episode, we interview Peter Kolchinsky, Managing Partner at RA Capital Management , LP and author of The Great American Drug Deal, about the state of drug development in the light of current events in policymaking.In this episode, we discuss:The investor's paradox and expecting drugs to failWhy the market, not the government, should steer drug developmentThe mortgage vs. rent analogyWhy insurance is essential to drug developmentHow a trust in healthcare allows global society to functionAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

How does an MIT senior year capstone project evolve into an early-stage biotech that creates wearable solutions for Parkinson's tremors?Listen to Daniel Carballo speak about the story of Encora Therapeutics in our MIT takeover episode, hosted by guest Lindsay Androski Founder, President, and CEO at Roivant Social Ventures and President, Board Member at Incubate Coalition. In this episode, we discuss:The innovation behind the first wearable prototypeDaniel's decision to become an entrepreneurHis company's North Star: improving patients' livesThe role of venture capital in the commercialization processAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform. Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

As we follow innovation along the R&D value chain, we come across some compelling contributions to the healthcare ecosystem.Venture capital investors. Causal inference. Real world evidence.In this episode, we interview three guests about a collaboration story that represents the best of a healthy healthcare ecosystem:Janis Naeve, Managing Director, Amgen Ventures at Amgen and Incubate Board TreasurerBrian Bradbury , Vice President of Center for Observational Research at Amgen and Adjunct Professor of Epidemiology at UCLAAlan Brookhart, Founder and Chief Scientist at NoviSci and Professor of Population Health Sciences at Duke UniversityIn this episode we discuss:How Amgen fosters relationships among scientistsThe difference between machine learning and causal inferenceThe origin story of NoviSciHow COVID has affected a fruitful partnershipAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform. Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player.

The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly?In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates , about what would change in biopharma if price controls were implemented.In this episode, we discuss:The close relationship between economy and drug developmentThe U.S.'s role in developing over 40% of the world's new medicinesThe potential reduction of biopharma global revenues by 19%What it means globally when 8-15 fewer medicines are made per decadeSome flaws in the health technology assessment (HTI) regarding clinical trialsIncubate Policy Lab is the research arm of Incubate Coalition, where we will be releasing reports, whitepapers, and hosting events in partnership with Charles Richards Associates. You can visit our website for more information.We will be releasing an analysis on the CBO report and how HR 3 will impact life sciences R&D, and another report where we analyze price controls from the venture capital perspective. We also hosted a roundtable, and will be releasing an analysis our findings from experts who attended the event.As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

What goes into a bottle of new medicine is more than the proverbial 15 years and $2 billion. It takes great science, certainly, but it also takes 15 years of relationships.No one can make medicine alone, not even Big Pharma. Collaboration, innovation, and industry relationships are key to bringing life-saving medicine to market.In this episode, I interview Imran Nasrullah, Vice President & Head, Open Innovation Center North America - East at Bayer Pharmaceuticals, about strengthening relationships within the biotech ecosystem.In this episode we discuss:The importance of industry relationships in making medicineHow relationships mitigate the challenge of drug developmentMentoring options for small, innovative companiesRelying on partners to actualize different paths to commercializationAs we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform. Listening on a desktop & can't see the links? Just search for Making Medicine in your favorite podcast player. 

High cost out-of-pocket drugs and obstacles to reduce those prices for patients plague the health industry. With patients in mind, organizations are looking to invest and bring drugs directly to market.Gaurav Gupta and Hugo Beekman, Co-Founders of Ascendant BioCapital, join the show to discuss their organization and how they're focusing on drugs that truly make a difference for patients.What we talked about:The Founding of Ascendant BioCapitalThe Medical & Investing Backgrounds of the FoundersImpactful Experiences in the IndustryTestifying Before Congress & Issues with Out-Of-Pocket CostsImportance of Intellectual Property to Biotech To hear more interviews like this one, subscribe to the Making Medicine Podcast on Apple Podcasts, Spotify, or your preferred podcast platform.

As it turns out, many perceptions about the pharmaceutical industry are based without all of the facts.That's why we're sitting down to understand the data with Ravi Mehrotra, Thought Leader and former Senior Managing Director of Biotechnology Equity Research at Evercore ISI.What we talked about:- Defining WBPI while taking a closer look at the industry- The reality that winners pay for all the losers- Risk and profitability- HR3 legislation- Wall Street's position on the drug pricing debateCheck out these resources we mentioned during the podcast:- HR 3 legislationAs we continue this new journey together, we would love to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

Intellectual property (IP) rights have been the driving force behind innovation and entrepreneurship. However, IP has more recently been seen in a negative light.Through the COVID-19 Pandemic, vaccine IP rights have come into question: should IP rights be waived when concerning an essential technology? Andrei Iancu, Former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, joins the podcast to discuss his views and concerns on IP rights:What we talked about:- The Benefits of IP- How Sentiment of IP Has Changed- Short, Medium, & Long Term Concerns to Waiving IP Rights- Where Concerns Should Be Focused & How to Improve IPCheck out the resources below for more information:- Andrei's LinkedIn- Our host: John Stanford's LinkedIn- www.incubatecoalition.comTo hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

The fight against Antimicrobial Resistance (AMR) is challenging due to financial, ethical, and legislative issues. Combating infectious disease can prove to be a risky financial investment but much less in comparison to the global impact if solutions are not researched. Alfonso Chang is the Managing Director of Relativity Healthcare Partners; he shares insight into the challenges and how to overcome them:- Investor Hesitancy- Higher clinical and ethical implications- Preference of existing therapies over new ones- Unintended consequences from lawmakers due to drafted legislative languageCheck out the resources below for more information:- Alfonso's LinkedIn- Our host: John Stanford's LinkedInTo hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

In 1980, the Bayh-Dole Act was enacted by U.S. Congress, which changed how ownership of an invention is pursued. Almost 40 years later, how has this act fared?On Episode 1 of Making Medicine, John Stanford, Executive Director of Incubate Coalition, introduces Joseph Allen and Associates to cover:- How Bayh-Dole came to be, starting with Purdue University - The original intent of ‘march-in' rights and how it affects Bayh-Dole- Who was this act for, and how has it played out 40 years later?As we begin on this new journey together, we would love to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what's top of mind, what story you want to hear, or what you find interesting!To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

From chance meetings to risky investments, Making Medicine explores the origin stories of life changing medication and how patients, corporations and investment communities benefit from understanding it. On today's episode, Kelsey Kohrs, Producer at Sweet Fish Media and John Stanford, Executive Director of Incubate Coalition introduce Making Medicine, a podcast dedicated to sharing life science stories that have led to scientific breakthroughs. These stories will cover:- What are the different steps of the drug development process?- How can we sustain future innovation in the life sciences?-When chance meetings have led to life changing drug innovationAs we begin on this new journey together, we would love to hear from you, the listener. What's interesting? What do you want to hear more of? Is there a story that you've heard of that you'd like our team to dig in to? Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org.To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.